Skip to content
DraconiticResearch
Search Sources API
203,952 studies31 sourcesUpdated 48 min ago
Peer-reviewedCC BYPharmaceutics

Functional Delivery of Nanoimmunotherapies in Pancreatic Ductal Adenocarcinoma: A Barrier-Informed Pharmaceutics Framework

  • Baodan Xu1
  • Dan Wei2
  • Kaishan Tao2
  • Yang Wang2
  1. 1School of Medicine, , Xi’an 710069, China
  2. 2Department of Hepatobiliary Surgery, , Xi’an 710032, China
Read full textPDFCite

Related

  1. Gut Microbiome Compositional and Functional Signatures Associated with Chemotherapy Response in Pancreatic Ductal Adenocarcinoma: An Exploratory Cohort Study.
    Erica Pizzocaro, Matteo Soverini, Gian Luca Salvagno +7
    MetabolitesPeer-reviewedCC BYFull textMolecular biology & gene regulationEurope PMC
  2. Context-Dependent Spatial and Functional Roles of CD44 Across Pancreatic Ductal Adenocarcinoma States
    Bin Fu, Yingying Tan, Yaxin Chen +6
    CancersPeer-reviewedCC BY 4.0Full textOncologyCrossrefEurope PMC
  3. Liver–Lung Organotropism in Pancreatic Ductal Adenocarcinoma: A Five-Stage Framework
    Baodan Cong, Kunfei Deng, Yu Du +1
    Cancer Management and ResearchPeer-reviewedCC BY-NC 4.0Full textOncologyPMC
  4. BIMS-GA: Adaptive Multi-Objective Optimization for Network-Aware Pancreatic Ductal Adenocarcinoma Biomarker Discovery
    Life (Basel, Switzerland)Peer-reviewedCC BYFull textEurope PMC
  5. Borderline resectable pancreatic ductal adenocarcinoma: a narrative review
    Rupesh Thapa Chhetri, Krisha Maharjan
    Annals of medicine and surgery (2012)Peer-reviewedCC BY-NDFull textGeneral medicineEurope PMC

Cite

BibTeXRIS
BibTeX
@article{xu2026functional,
  title = {{Functional Delivery of Nanoimmunotherapies in Pancreatic Ductal Adenocarcinoma: A Barrier-Informed Pharmaceutics Framework}},
  author = {Baodan Xu and Dan Wei and Kaishan Tao and Yang Wang},
  journal = {Pharmaceutics},
  year = {2026},
  month = oct,
  url = {https://europepmc.org/article/PMC/PMC13708326},
  note = {CC BY},
}
RIS
TY  - JOUR
TI  - Functional Delivery of Nanoimmunotherapies in Pancreatic Ductal Adenocarcinoma: A Barrier-Informed Pharmaceutics Framework
AU  - Baodan Xu
AU  - Dan Wei
AU  - Kaishan Tao
AU  - Yang Wang
PY  - 2026
DA  - 2026/10/01
JO  - Pharmaceutics
UR  - https://europepmc.org/article/PMC/PMC13708326
SN  - 1999-4923
ER  -